Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetes Mellitus, Type 2: full-pipeline trial registry
63 of 351 indexed Diabetes Mellitus, Type 2 trials are currently recruiting.
Corpus placement: #18 of 28,707 conditions by registered trial count.
351 US clinical trials · 63 currently recruiting · #18 of 28,707 conditions by registered trial count
Diabetes Mellitus, Type 2: 351 US clinical trials tracked, 63 recruiting.
Diabetes Mellitus, Type 2 is the subject of 351 registered US clinical trials on ClinicalTrials.gov, 63 of them currently open to new participants. 100 are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 48 of these trials.
Enrollment posture brief
Registry condition diabetes-mellitus-type-2
OPEN 63 | RECR 18% | LATE 100 | EARLY 80 | RANK #18 | SPON 48
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (18% recruiting · 39 trials)
Diabetes Mellitus, Type 2 lists 63 open slots (18% of 351 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetes Mellitus, Type 2 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetes Mellitus, Type 2 is recruiting below its size-band peers.
63 of 351 indexed trials (17.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diabetes Mellitus, Type 2 trials is spread across many organizations.
Novo Nordisk A/S accounts for 48 of 351 trials (13.7%). 143 distinct sponsors appear on at least one study for this condition label.
-
Typical Diabetes Mellitus, Type 2 enrolment sits around 150 participants.
Median target enrolment is 150 among the 349 trials that report a genuine target (sentinel values excluded). 142 of those (40.7%) plan for fewer than 100 participants.
-
Diabetes Mellitus, Type 2 research is mostly interventional.
321 interventional and 30 observational studies make up this index (91.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
351 total, page 6 of 8
A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes
Pfizer
NCT01469065
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus
Kaneq Bioscience Limited
NCT02445911
T-UP: Engaging Vulnerable Students in Diabetes Prevention
University of California, Los Angeles
NCT06385015
Assessment of Mealtime Bolus Insulin Behavior
Eli Lilly and Company
NCT03368807
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Novartis Pharmaceuticals
NCT03005288
Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00813228
Food and Education Effects on Diabetes Study
Johns Hopkins University
NCT04034511
PDD in Type 2 Diabetes w/wo Diastolic Dysfunction
Mayo Clinic
NCT03744975
A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump
Novo Nordisk A/S
NCT00115973
Diabetes Visual Function Supplement Study
ZeaVision
NCT01646047
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
The Cleveland Clinic
NCT06533527
Development and Feasibility Testing of DM-BOOST Intervention.
Daniel Amante
NCT04710940
A Study of Multiple Doses of LY2922470 in Participants With Diabetes
Eli Lilly and Company
NCT01867216
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
GlaxoSmithKline
NCT01128621
Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
Pfizer
NCT04305587
Determining the Effect on Patients of Internet-Based Diabetes Disease Management
Robert Wood Johnson Foundation
NCT00220207
A Study Of PF-05175157 In Healthy Volunteers
Pfizer
NCT01274663
The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin
Novo Nordisk A/S
NCT01043510
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans
University of Colorado, Denver
NCT03077360
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers
Novo Nordisk A/S
NCT01489644
Effect of Renal Impairment on the Pharmacokinetics of NN9535
Novo Nordisk A/S
NCT00833716
Comparison of Glycemic Control Achieved With 2 Different Needles
Novo Nordisk A/S
NCT00572052
Heart Rate Variability in Response to Metformin Challenge
Woodinville Psychiatric Associates
NCT02500628
Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes
Pfizer
NCT01272804
Onduo Virtual Diabetes Clinic Study
Verily Life Sciences
NCT03865381
In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus
GlaxoSmithKline
NCT00354536
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients
PLx Pharma
NCT02008942
A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus
Hoffmann-La Roche
NCT01789788
Advanced Glycation Endproducts and Bone Material Strength in T2D Treated With Pyridoxamine
Columbia University
NCT03778580
Diabetes Risk Education and Communication Trial
Northwestern University
NCT03283657
A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)
Novo Nordisk A/S
NCT05823948
Virta Intervention in CommuniTies in cOloRado (VICTOR-Pilot)
Colorado Prevention Center
NCT04807218
Exercise and the Receptor for Advanced Glycation End Products (RAGE)
University of Michigan
NCT03534687
A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin
GlaxoSmithKline
NCT00519480
Exercise Training for Patients With Poor Leg Circulation
US Department of Veterans Affairs
NCT00118560
A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus
Oramed
NCT04564846
Green Digital Diabetes Waste Project
Florida State University
NCT06071325
Yoga as a Complementary Therapy for Adults With Type 2 Diabetes
The Miriam Hospital
NCT02607566
Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
Takeda
NCT00957268
Models of Nutrition From Continuous Glucose Monitors
Texas A&M University
NCT04991142
A Study of RO6807952 in Patients With Diabetes Mellitus Type 2
Hoffmann-La Roche
NCT01358929
Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
GlaxoSmithKline
NCT01475734
Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
Bristol-Myers Squibb
NCT00094991
Study OF PF-06882961 IN Participants With Type 2 Diabetes Mellitus With Varying Degrees OF Renal Impairment AND Participants Without Renal Impairment
Pfizer
NCT04616027
Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI
University of Florida
NCT03437044
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
Boehringer Ingelheim
NCT01867307
Diabetes Homeless Medication Support
Hennepin Healthcare Research Institute
NCT05258630
A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects
GlaxoSmithKline
NCT00559884
Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid
University of Missouri-Columbia
NCT03648996
Redox Imbalance and the Development of Cystic Fibrosis Diabetes
Emory University
NCT02202876
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 42 |
| Phase 2 | 38 |
| Phase 3 | 74 |
| Phase 4 | 26 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetes Mellitus, Type 2 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetes Mellitus, Type 2 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetes Mellitus, Type 2 page
351 registered trials, 63 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 63 Diabetes Mellitus, Type 2 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novo Nordisk A/S sponsors the most Diabetes Mellitus, Type 2 trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes Mellitus, Type 2 condition card totals 351 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.